Discussion Evidence linking 7nAChR dysfunction to ASD A number of animal and human studies (Table
astragaloside IV from Astragalus root, known to stimulate telomerase activity
The goal is to saturate the area around the damaged fascia, not to inject directly into the ligament itself, which could cause further injury
Trial Structure Duration: 48 weeks of treatment Participants: 338 adults randomized 2:1:1:1:1:2:2 to placebo or retatrutide groups Doses tested: 1mg, 4mg, 8mg, 12mg (all with slow titration from 2mg starting dose) Lifestyle intervention: All participants received counseling on diet (500 kcal/day deficit) and exercise (150 min/week) Primary endpoint: Percent weight change at 24 weeks Key secondary endpoints: Weight change at 48 weeks, proportion achieving 5%, 10%, 15% loss The trial used a slow titration protocol to minimize side effects: all groups except the 1mg dose started at 2mg weekly and escalated every 4 weeks
Yet many experts argue that lesion characteristics, in addition to size, should be considered in the classification criteria and ultimately risk stratification
